Abbott Vascular

3200 Lakeside Dr.
Santa Clara
CA
95054
USA
Phone: 
(408) 845-3000
http://www.abbottvascular.com
Product Categories: Embolic Protection Devices Stents Stents, Bare Metal Stents, Carotid Stents, Drug Eluting Stents, Peripheral Vascular Closure Devices

Related Articles

Heart Valve Repair

Two Real-World European Studies of Abbott's Minimally Invasive MitraClip Device Demonstrate Positive Outcomes for Patients with Mitral Regurgitation
FDA Advisory Committee Supports MitraClip for Patients With Significant Mitral Regurgitation Who Are Too High Risk for Surgery
Novel Percutaneous Approaches for Mitral Valve Regurgitation
MitraClip Offers Significant Improvements for Both Functional, Degenerative MR in High-Risk Patients
Abbott Presents New Data for Key Vascular Products at TCT 2011
MitraClip Shows Benefit For Heart Failure Patients Who Do Not Respond to CRT
Mitral Valve Repair by Catheter Compares Favorably With Open-Heart Surgery
Trial Data Show Benefits for Mitral Valve Clip After Two Years
Transcatheter Mitral Repair Relieves Symptoms Without Surgery
EVEREST II Trial Data Suggests Promise of Investigational Mitral Valve Repair Device
Abbott to Acquire Evalve, a Leader in Percutaneous Mitral Valve Repair
MitraClip

Structural Heart

Two Real-World European Studies of Abbott's Minimally Invasive MitraClip Device Demonstrate Positive Outcomes for Patients with Mitral Regurgitation
FDA Advisory Committee Supports MitraClip for Patients With Significant Mitral Regurgitation Who Are Too High Risk for Surgery
Novel Percutaneous Approaches for Mitral Valve Regurgitation
MitraClip Offers Significant Improvements for Both Functional, Degenerative MR in High-Risk Patients
Structural Heart Occluders in Development
Transcatheter Mitral Repair Relieves Symptoms Without Surgery
EVEREST II Trial Data Suggests Promise of Investigational Mitral Valve Repair Device
Abbott to Acquire Evalve, a Leader in Percutaneous Mitral Valve Repair

Hybrid OR

Two Real-World European Studies of Abbott's Minimally Invasive MitraClip Device Demonstrate Positive Outcomes for Patients with Mitral Regurgitation
FDA Advisory Committee Supports MitraClip for Patients With Significant Mitral Regurgitation Who Are Too High Risk for Surgery

Balloon Catheter

Market Drivers for U.S. PTCA and Cutting Balloon Catheters
FDA Approves Use of Common Abbott Devices to Treat for Coronary CTOs
Next-Generation FoxCross PTA Catheter Aimed at PAD
Abbott Launches VOYAGER NC Coronary Balloon Catheter
VOYAGER NC Coronary Dilatation Catheter Features a Specialized Distal Tip

Cath Lab

Market Drivers for U.S. PTCA and Cutting Balloon Catheters
Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
FDA Approves Use of Common Abbott Devices to Treat for Coronary CTOs
Interventional Cardiology Devices Forecast
Abbott Initiates U.S. Trial for Fully Bioresorbable Stent
FDA Approves Abbott’s Next-Generation Xience Xpedition Drug-Eluting Stent
Low Clopidogrel Responsiveness Predicts Stent Thrombosis, Heart Attack
Analyst Insight: Abbott’s Absorb is the New Face of the Stent Industry
Abbott Begins Commercial Launch of the Absorb Bioresorbable Stent
Cardiac Stent Usage Among U.S. Cardiologists
Abbott, St. Jude Medical Broaden Alliance for Cardiovascular Products
Trial Data Shows Superior Efficacy of Promus Element Compared to Xience V
When to Consider Revascularization of Coronary Chronic Total Occlusions
Interventional Cardiology Device Markets to Grow in Pakistan, Saudi Arabia, South Africa, Turkey
Advances in Vascular Closure Technology
Abbott Initiates Trial for Drug-Eluting Bioresorbable Peripheral Stent
Abbott Wants to Prove Stents Trump CABG
Abbott Enrolls First U.S. Patient in Trial Comparing Xience to CABG
FDA Clears Carotid Stenting for use in Standard-Surgical Risk Patients
FDA Clears Wireless Point-of-Care Blood Testing System
First Bioresorbable Stent Cleared in Europe
Everolimus Stents Pickup Japanese Market Share
PROSPECT Study Provides New Insight into Role of Vulnerable Plaque in Heart Disease
XIENCE Outperforms TAXUS Express in SPIRIT IV
XIENCE V Demonstrates Low Rates of Repeat Procedure, Thrombosis, MACE in SPIRIT V

Catheter

Market Drivers for U.S. PTCA and Cutting Balloon Catheters

Stents, Drug Eluting

Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
Interventional Cardiology Devices Forecast
Abbott Initiates U.S. Trial for Fully Bioresorbable Stent
FDA Approves Abbott’s Next-Generation Xience Xpedition Drug-Eluting Stent
Abbott Announces CE Mark and European Launch of Next-Generation Xience Xpedition Drug-Eluting Stent
Cardiac Stent Usage Among U.S. Cardiologists
Japan Clears Abbott Xience Prime Drug-Eluting Stent
Trial Data Shows Superior Efficacy of Promus Element Compared to Xience V
The Future of Coronary Stenting
Abbott Initiates Trial for Drug-Eluting Bioresorbable Peripheral Stent
ABSORB II Trial Will Compare Abbott's Bioresorbable Stent to Metallic DES
Comparison of Xience V, Resolute Stents Shows Similar, Low Rates of Thrombosis
Abbott Presents New Data for Key Vascular Products at TCT 2011
FDA Clears Xience Prime Coronary Stent
Abbott Wants to Prove Stents Trump CABG
Abbott Enrolls First U.S. Patient in Trial Comparing Xience to CABG
Cardiovascular Stents – Novel Designs, Polymers and New Entries into Market Top Industry Trends
Lower Stent Thrombosis Found With Xience Than With Bare Metal Stent
The Next Generation of DES
FDA Approves Xience Nano Stent to Treat Small Coronary Vessels
Trial Results Show Positive Performance for Everolimus-Eluting Stent
Xience Prime Granted European Approval to Treat Lower Leg Vessels
First Bioresorbable Stent Cleared in Europe
Strong Clinical Results for Bioresorbable Vascular Scaffold
Drug-Eluting Stent Shows Strong Performance in Second Study
Bioresorbable Stent Continues to Show Good Clinical Results
Boston Scientific Plans Stent Rematch With Xience
Head-to-Head Study Shows Stent Matches Performance of Market Leader
SPIRIT IV Trial Results Confirm Everolimus Stent’s Superior Safety, Efficacy
Everolimus Stents Pickup Japanese Market Share
SPIRIT Results Show Continued Positive Results Market-Leading Stent
The Future of Stent Technology Highlighted at TCT 2009
New ABSORB EXTEND Trial Studies Bioabsorbable Stent in 1,000 Patients
XIENCE PRIME, XIENCE V Receive Indications in Europe to Treat Diabetes Patients
Harvard Enrolls First Patients to Advance Understanding of Dual Anti-Platelet Therapy Following PCI
XIENCE Outperforms TAXUS Express in SPIRIT IV
PROMUS, First-Generation TAXUS Express Stents Perform Strongly in SPIRIT III Trial
Trends in Coronary, Carotid and Peripheral Stents
New Designs May Ease Bifurcation Stenting
Advancements in Drug-Eluting Stents
Dissolving Stents May Offer New Options in the Next Decade
China Approves Use of Abbott’s XIENCE V Drug Eluting Stent
Health Canada Approves Abbott's XIENCE V Drug Eluting Stent
Abbott Launches Next-Generation XIENCE PRIME DES in International Markets
Abbott Expands XIENCE V USA Trial to Enroll Patients into Dual Anti-Platelet Therapy Trial
Abbott Receives CE Mark for Xience PRIME Drug-Eluting Stent
Abbott Begins Trial for Next-Generation Xience PRIME DES
XIENCE V Demonstrates Low Rates of Repeat Procedure, Thrombosis, MACE in SPIRIT V
Abbott's XIENCE V Shows Clinical Advantages Over TAXUS Express2, TAXUS Liberte Between Two, Three Years
Abbott's XIENCE V Cleared for Treatment of Coronary Artery Disease
Trial Data Reveals XIENCE V Outperforms TAXUS Express2 in Reducing MACE at Two Years
Abbott Begins U.S. Study of XIENCE V Drug Eluting
Abbott’s XIENCE V Drug-Eluting Stent Wins Chicago Innovation Award
New Data Shows Abbott’s Bioabsorbable DES is Absorbed Within Two Years
Data Indicates Abbott's XIENCE V Stent Patients Are at Lower Risk of Death, Heart Attack
Abbott Submits XIENCE V Application for Approval in Japan
Abbott’s Bioabsorbable DES Shows No Thrombosis at One Year
Abbott's 2.25 mm XIENCE V Stent Gets CE Mark Approval
Abbott Gains Reimbursement for XIENCE V DES in France
FDA Advisory Committee Recommends Approval of XIENCE
Clots Low with Abbott Stent for Two Years
Bioabsorbable DES Reports No Thrombosis at One Year
SPIRIT III Shows Less MACE for Xience than Taxus
Results from ABSORB Trial Positive Says Abbott
Judge Backs Abbott Over Medinol In Dispute on Heart-Stent License
Abbott Enrolls First Patient in Study on DES Treatment in Women
Fewer Stents Implanted in June
Abbott Submits XIENCE V Everolimus Eluting Coronary Stent System Application for FDA Approval
Abbott’s Absorbable Stent Showing No Thrombosis at Nine Months
DES Trial to Study Complexities of CVD in Women
French Patent Court Rules Against Abbott’s DES
Positive Xience V Results for Diabetics
Abbott Goes Full Throttle with Xience V
Xience Xpedition
Esprit drug-eluting bioresorbable stent
Xience nano 2.25 mm stent

Blood Testing

Galectin-3 Test May Help Identify Patients at Highest Risk for a Worse Prognosis in Heart Failure
Abbott Evolves to Focus on Diagnostics, with New High-Sensitivity Heart Attack Diagnostic Test
New Test May Reduce Time in Diagnosing Heart Attacks, Assist in Determining Risk for Future MI
Studies Find New Diagnostic Tests for Heart Conditions Will Reduce Time to Heart Attack Treatment
Advances in Point-of-Care Anticoagulation Testing Systems
Findings From Recent JAMA Study Show Increased Detection of Heart Attacks
FDA Clears Wireless Point-of-Care Blood Testing System
Coronary Heart Disease Genetic Marker Test Cleared in Europe
FDA Clears Home Blood Coagulation Testing System
Architect Stat Troponin-I assay

Heart Failure Treatments

Galectin-3 Test May Help Identify Patients at Highest Risk for a Worse Prognosis in Heart Failure
MitraClip Shows Benefit For Heart Failure Patients Who Do Not Respond to CRT
MitraClip

Clinical Trial/Study

New Data Reinforce Strong Long-Term Clinical Performance of Absorb Bioresorbable Vascular Stent
Abbott Initiates U.S. Trial for Fully Bioresorbable Stent
Novel Percutaneous Approaches for Mitral Valve Regurgitation
Low Clopidogrel Responsiveness Predicts Stent Thrombosis, Heart Attack
Trial Data Shows Superior Efficacy of Promus Element Compared to Xience V
Abbott Initiates Trial for Drug-Eluting Bioresorbable Peripheral Stent
ABSORB II Trial Will Compare Abbott's Bioresorbable Stent to Metallic DES
New Data Reinforce Clinical Performance of Absorb Bioresorbable Stent
Comparison of Xience V, Resolute Stents Shows Similar, Low Rates of Thrombosis
MitraClip Offers Significant Improvements for Both Functional, Degenerative MR in High-Risk Patients
Economic Study Demonstrates Cost-Effectiveness Of Impella Presented At TCT 2011
Abbott Presents New Data for Key Vascular Products at TCT 2011
Abbott Wants to Prove Stents Trump CABG
Abbott Enrolls First U.S. Patient in Trial Comparing Xience to CABG
ABSORB Clinical Trial Begins for Treatment of Below-the-Knee Critical Limb Ischemia
Lower Stent Thrombosis Found With Xience Than With Bare Metal Stent
MitraClip Shows Benefit For Heart Failure Patients Who Do Not Respond to CRT
First Patient in Japan Treated With Abbott's Bioresorbable Stent in Global Clinical Trial
HERCULES Study Shows Renal Stenting Significantly Reduces Blood Pressure
Mitral Valve Repair by Catheter Compares Favorably With Open-Heart Surgery
Trial Data Show Benefits for Mitral Valve Clip After Two Years
Bioresorbable Stent Demonstrates Positive One-Year Results
Trial Results Show Positive Performance for Everolimus-Eluting Stent
Strong Clinical Results for Bioresorbable Vascular Scaffold
Drug-Eluting Stent Shows Strong Performance in Second Study
Data presented on Xience V, Abbott's vascular pipeline
Bioresorbable Stent Continues to Show Good Clinical Results
Carotid Stent Maker Seeks Expanded FDA Indication
Boston Scientific Plans Stent Rematch With Xience
Head-to-Head Study Shows Stent Matches Performance of Market Leader
Transcatheter Mitral Repair Relieves Symptoms Without Surgery
SPIRIT IV Trial Results Confirm Everolimus Stent’s Superior Safety, Efficacy
SPIRIT Results Show Continued Positive Results Market-Leading Stent
EVEREST II Trial Data Suggests Promise of Investigational Mitral Valve Repair Device
Surgery, Stenting of Carotids Similar in Safety, Efficacy
The Future of Stent Technology Highlighted at TCT 2009
New ABSORB EXTEND Trial Studies Bioabsorbable Stent in 1,000 Patients
VIVA 2009 Late-Breaking Trials Highlight Advances in PAD Treatments
PROSPECT Study Provides New Insight into Role of Vulnerable Plaque in Heart Disease
Harvard Enrolls First Patients to Advance Understanding of Dual Anti-Platelet Therapy Following PCI
XIENCE Outperforms TAXUS Express in SPIRIT IV
PROMUS, First-Generation TAXUS Express Stents Perform Strongly in SPIRIT III Trial
Abbott Expands XIENCE V USA Trial to Enroll Patients into Dual Anti-Platelet Therapy Trial
Abbott Begins Trial for Next-Generation Xience PRIME DES
XIENCE V Demonstrates Low Rates of Repeat Procedure, Thrombosis, MACE in SPIRIT V
Abbott's XIENCE V Shows Clinical Advantages Over TAXUS Express2, TAXUS Liberte Between Two, Three Years
U.S. Study of Abbott’s Absolute Pro Peripheral Stent System for Iliac Artery Disease Begins
Trial Data Reveals XIENCE V Outperforms TAXUS Express2 in Reducing MACE at Two Years
Abbott Begins U.S. Study of XIENCE V Drug Eluting
New Data Shows Abbott’s Bioabsorbable DES is Absorbed Within Two Years
Carotid Artery Stenting Trials Meet AHA Guidelines
SPIRIT III Shows Less MACE for Xience than Taxus
Results from ABSORB Trial Positive Says Abbott
Abbott Submits XIENCE V Everolimus Eluting Coronary Stent System Application for FDA Approval
MitraClip

Stents, Bioresorbable

New Data Reinforce Strong Long-Term Clinical Performance of Absorb Bioresorbable Vascular Stent
Interventional Cardiology Devices Forecast
Abbott Initiates U.S. Trial for Fully Bioresorbable Stent
Analyst Insight: Abbott’s Absorb is the New Face of the Stent Industry
Abbott Begins Commercial Launch of the Absorb Bioresorbable Stent
The Future of Coronary Stenting
Abbott Initiates Trial for Drug-Eluting Bioresorbable Peripheral Stent
ABSORB II Trial Will Compare Abbott's Bioresorbable Stent to Metallic DES
New Data Reinforce Clinical Performance of Absorb Bioresorbable Stent
Abbott Presents New Data for Key Vascular Products at TCT 2011
Wall Street Journal Award Recognizes Abbott’s Absorb Stent
Abbott Wants to Prove Stents Trump CABG
Cardiovascular Stents – Novel Designs, Polymers and New Entries into Market Top Industry Trends
New Directions for Stent Technology
ABSORB Clinical Trial Begins for Treatment of Below-the-Knee Critical Limb Ischemia
First Patient in Japan Treated With Abbott's Bioresorbable Stent in Global Clinical Trial
Absorb Bioresorbable Vascular Scaffold
Esprit drug-eluting bioresorbable stent

CTO Crossing catheters

FDA Approves Use of Common Abbott Devices to Treat for Coronary CTOs
When to Consider Revascularization of Coronary Chronic Total Occlusions
VIVA 2009 Late-Breaking Trials Highlight Advances in PAD Treatments

Guidewires

FDA Approves Use of Common Abbott Devices to Treat for Coronary CTOs
HI-TORQUE BMW Guide Wire Has Two Coatings for Easier Movement
HI-TORQUE Versacore .035 Guide Wire Aids in PAD Treatment

Stents, Bare Metal

Interventional Cardiology Devices Forecast
The Future of Coronary Stenting
Cardiovascular Stents – Novel Designs, Polymers and New Entries into Market Top Industry Trends
Lower Stent Thrombosis Found With Xience Than With Bare Metal Stent
FDA Clears RX Herculink Elite Renal Stent System
Trends in Coronary, Carotid and Peripheral Stents
New Designs May Ease Bifurcation Stenting
Dissolving Stents May Offer New Options in the Next Decade
Xience Xpedition
RX Herculink Elite Renal Stent

Stents

Interventional Cardiology Devices Forecast
Analyst Insight: Abbott’s Absorb is the New Face of the Stent Industry
Abbott Begins Commercial Launch of the Absorb Bioresorbable Stent
Abbott Announces CE Mark and European Launch of Next-Generation Xience Xpedition Drug-Eluting Stent
Cardiac Stent Usage Among U.S. Cardiologists
Abbott, St. Jude Medical Broaden Alliance for Cardiovascular Products
Japan Clears Abbott Xience Prime Drug-Eluting Stent
The Future of Coronary Stenting
Wall Street Journal Award Recognizes Abbott’s Absorb Stent
Abbott Wants to Prove Stents Trump CABG
Abbott Enrolls First U.S. Patient in Trial Comparing Xience to CABG
Cardiovascular Stents – Novel Designs, Polymers and New Entries into Market Top Industry Trends
New Directions for Stent Technology
First Patient in Japan Treated With Abbott's Bioresorbable Stent in Global Clinical Trial
HERCULES Study Shows Renal Stenting Significantly Reduces Blood Pressure
FDA Clears RX Herculink Elite Renal Stent System
The Next Generation of DES
Stenting to Replace Endarterectomy?
FDA Approves Xience Nano Stent to Treat Small Coronary Vessels
FDA Clears Carotid Stenting for use in Standard-Surgical Risk Patients
Bioresorbable Stent Demonstrates Positive One-Year Results
First Bioresorbable Stent Cleared in Europe
Strong Clinical Results for Bioresorbable Vascular Scaffold
Drug-Eluting Stent Shows Strong Performance in Second Study
Data presented on Xience V, Abbott's vascular pipeline
Bioresorbable Stent Continues to Show Good Clinical Results
Boston Scientific Plans Stent Rematch With Xience
SPIRIT Results Show Continued Positive Results Market-Leading Stent
Surgery, Stenting of Carotids Similar in Safety, Efficacy
The Future of Stent Technology Highlighted at TCT 2009
New ABSORB EXTEND Trial Studies Bioabsorbable Stent in 1,000 Patients
Trends in Coronary, Carotid and Peripheral Stents
New Designs May Ease Bifurcation Stenting
Dissolving Stents May Offer New Options in the Next Decade
Medtronic, Abbott Settle Stent Litigation
Abbott Advances Fully Bioabsorbable DES With Next Phase of Clinical Trial
Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent Published
Trial Data Reveals XIENCE V Outperforms TAXUS Express2 in Reducing MACE at Two Years
Abbott’s XIENCE V Drug-Eluting Stent Wins Chicago Innovation Award
New Data Shows Abbott’s Bioabsorbable DES is Absorbed Within Two Years
Results from ABSORB Trial Positive Says Abbott
Abbott Initiates HERCULES Renal Stent Trial
Abbott Expects Stent FDA Review
Carotid Artery Stent Reduces Plaque Release
Xience Xpedition
RX Herculink Elite Renal Stent

Cardiac Diagnostics

Abbott Evolves to Focus on Diagnostics, with New High-Sensitivity Heart Attack Diagnostic Test
Studies Find New Diagnostic Tests for Heart Conditions Will Reduce Time to Heart Attack Treatment
Findings From Recent JAMA Study Show Increased Detection of Heart Attacks
FDA Clears Home Blood Coagulation Testing System
PROSPECT Study Provides New Insight into Role of Vulnerable Plaque in Heart Disease
Abbott Recalls ARCHITECT STAT Troponin-I Test
Architect Stat Troponin-I assay

Point of Care Testing

New Test May Reduce Time in Diagnosing Heart Attacks, Assist in Determining Risk for Future MI
Advances in Point-of-Care Anticoagulation Testing Systems
FDA Clears Wireless Point-of-Care Blood Testing System
Patients with Chest Pain Benefit from Patient-Side POC Testing in ED

Antiplatelet Therapy

Low Clopidogrel Responsiveness Predicts Stent Thrombosis, Heart Attack
Harvard Clinical Research Institute Successfully Completes Randomization in DAPT Study
Advances in Point-of-Care Anticoagulation Testing Systems

Pharmaceuticals

Low Clopidogrel Responsiveness Predicts Stent Thrombosis, Heart Attack
Harvard Clinical Research Institute Successfully Completes Randomization in DAPT Study
Advances in Point-of-Care Anticoagulation Testing Systems
Obesity Drug Withdrawn in U.S. Due to Cardiovascular Complications
FDA Clears Home Blood Coagulation Testing System
New Dosage Strengths Sought for Cholesterol-Lowering Medication
Harvard Enrolls First Patients to Advance Understanding of Dual Anti-Platelet Therapy Following PCI
Abbott Expands XIENCE V USA Trial to Enroll Patients into Dual Anti-Platelet Therapy Trial
Zetia, Vytorin Lose Substantial Patient Share in Dyslipidemia Treatment
New Drug Therapy Approved for Cholesterol Management
Abbott, AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR
FDA Approves Abbott’s New Cholesterol Management Drug
Abbott's SIMCOR Lowered Plaque-Promoting Non-HDL Cholesterol in Study
FDA Clears Abbott’s “Good Cholesterol” Drug

Peripheral Arterial Disease (PAD) Treatment Devices

FDA Clears Omnilink Elite Vascular Balloon-Expandable Stent for Iliac Artery Lesions
Abbott Initiates Trial for Drug-Eluting Bioresorbable Peripheral Stent
ABSORB Clinical Trial Begins for Treatment of Below-the-Knee Critical Limb Ischemia
Xience Prime Granted European Approval to Treat Lower Leg Vessels
VIVA 2009 Late-Breaking Trials Highlight Advances in PAD Treatments
HI-TORQUE Versacore .035 Guide Wire Aids in PAD Treatment
Next-Generation FoxCross PTA Catheter Aimed at PAD

Stents, Peripheral

FDA Clears Omnilink Elite Vascular Balloon-Expandable Stent for Iliac Artery Lesions
Abbott Initiates Trial for Drug-Eluting Bioresorbable Peripheral Stent
Cardiovascular Stents – Novel Designs, Polymers and New Entries into Market Top Industry Trends
HERCULES Study Shows Renal Stenting Significantly Reduces Blood Pressure
FDA Clears RX Herculink Elite Renal Stent System
Xience Prime Granted European Approval to Treat Lower Leg Vessels
VIVA 2009 Late-Breaking Trials Highlight Advances in PAD Treatments
Trends in Coronary, Carotid and Peripheral Stents
U.S. Study of Abbott’s Absolute Pro Peripheral Stent System for Iliac Artery Disease Begins
Abbott Vascular Takes Lead in PV Stent Market
Omnilink Elite Balloon-Expandable Stent System
Esprit drug-eluting bioresorbable stent
RX Herculink Elite Renal Stent

Atrial Fibrillation Therapies

Advances in Point-of-Care Anticoagulation Testing Systems

Optical Coherence Tomography (OCT)

Abbott, St. Jude Medical Broaden Alliance for Cardiovascular Products
Bioresorbable Stent Continues to Show Good Clinical Results
Everolimus Stents Pickup Japanese Market Share
Dissolving Stents May Offer New Options in the Next Decade
New Data Shows Abbott’s Bioabsorbable DES is Absorbed Within Two Years

EP Lab

Abbott, St. Jude Medical Broaden Alliance for Cardiovascular Products

FFR Catheters

Abbott, St. Jude Medical Broaden Alliance for Cardiovascular Products

Radial Access

Advances in Vascular Closure Technology

Hemostasis Management

Advances in Vascular Closure Technology

Vascular Closure Devices

Advances in Vascular Closure Technology
ProGlide Delivers Medicated Sutures to Seal the Femoral Access Site
StarClose SE Vascular Closure System Offers Ergonomic Design
StarClose SE Vascular Closure System Enables Fast, Secure Femoral Closure
StarClose SE Vascular Closure System Offers Ergonomic Design
Abbott Launches Next-Generation Vascular Closure System
Closure Device Reduces Infection Risk

Ventricular Assist Devices (VAD)

Economic Study Demonstrates Cost-Effectiveness Of Impella Presented At TCT 2011

Cardiovascular Surgery

Abbott Wants to Prove Stents Trump CABG
Abbott Enrolls First U.S. Patient in Trial Comparing Xience to CABG
Mitral Valve Repair by Catheter Compares Favorably With Open-Heart Surgery
Surgery, Stenting of Carotids Similar in Safety, Efficacy

Stents, Carotid

Cardiovascular Stents – Novel Designs, Polymers and New Entries into Market Top Industry Trends
Stenting to Replace Endarterectomy?
FDA Clears Carotid Stenting for use in Standard-Surgical Risk Patients
FDA Panel Suggests Expanding Carotid Stenting for Standard Risk Patients
Carotid Stent Maker Seeks Expanded FDA Indication
Surgery, Stenting of Carotids Similar in Safety, Efficacy
Carotid Artery Stent Provides Easy Placement
VIVA 2009 Late-Breaking Trials Highlight Advances in PAD Treatments
Trends in Coronary, Carotid and Peripheral Stents
Embolic Protection Reduces Complications
Carotid Artery Stenting Trials Meet AHA Guidelines

Hypertension Therapies

HERCULES Study Shows Renal Stenting Significantly Reduces Blood Pressure
FDA Clears RX Herculink Elite Renal Stent System

Cholesterol Test Kit

Coronary Heart Disease Genetic Marker Test Cleared in Europe

Genetic Testing

Coronary Heart Disease Genetic Marker Test Cleared in Europe

General Cardiology

First Bioresorbable Stent Cleared in Europe
PROSPECT Study Provides New Insight into Role of Vulnerable Plaque in Heart Disease
Abbott Launches VOYAGER NC Coronary Balloon Catheter
Abbott’s XIENCE V Drug-Eluting Stent Wins Chicago Innovation Award
New Data Shows Abbott’s Bioabsorbable DES is Absorbed Within Two Years

Cardiology Related

First Bioresorbable Stent Cleared in Europe

Structural Heart Occluders/Closure Devices

Structural Heart Occluders in Development

Embolic Protection Devices

Embolic Protection Prevent's Stroke During Carotid Stenting
Embolic Protection Reduces Complications
Abbott Launches of Next-Generation Embolic Protection System
Embolic Protection System Begins European Launch
Distal Embolization Risk Minimized, Filter Control Simplified

Intravascular Imaging Systems

PROSPECT Study Provides New Insight into Role of Vulnerable Plaque in Heart Disease

Intra-Vascular Ultrasound (IVUS)

PROSPECT Study Provides New Insight into Role of Vulnerable Plaque in Heart Disease

Catheters

Abbott Issues Recall of POWERSAIL Coronary Dilatation Catheters
Device Helps Deliver Stents and Balloons

Patient Safety

Abbott Issues Recall of POWERSAIL Coronary Dilatation Catheters

Pacemakers

Remote Monitoring of Implantable Devices is the Future

Implantable Cardiac Monitor (ICM)

Remote Monitoring of Implantable Devices is the Future

Remote Monitoring

Remote Monitoring of Implantable Devices is the Future

Implantable Cardioverter Defibrillators (ICD)

Remote Monitoring of Implantable Devices is the Future

Home Healthcare Monitor Device

Remote Monitoring of Implantable Devices is the Future

Cardiac Resynchronization Therapy Devices (CRT)

Remote Monitoring of Implantable Devices is the Future

Cardiology Products

Abbott Launches VOYAGER NC Coronary Balloon Catheter
Abbott’s XIENCE V Drug-Eluting Stent Wins Chicago Innovation Award
New Data Shows Abbott’s Bioabsorbable DES is Absorbed Within Two Years
Abbott, AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR

Blood Gas Analyzer

FDA OK's Abbott's Use of Blood Analyzer with CLIA Waiver